Table 1 Pretreatment characteristics in 107 esophageal cancer patients.
Surgery alone n = 45 | #CRT ± surgery n = 62 | p | Surgery alone n = 45 | CRT+ surgery n = 31 | p | |
|---|---|---|---|---|---|---|
Male/Female | 41/4 | 53/9 | 0.55 | 41/4 | 27/4 | 0.71 |
Age median (range), yr | 69 (39-83) | 63 (46-79) | 0.22 | 69 (39-83) | 58 (46-79) | 0.032 |
† PS WHO 0 | 9 (20) | 16 (25.8) | 0.60 | 9 (20) | 10 (32.3) | 0.08 |
PS WHO 1 | 31 (68.9) | 42 (67.7) | 31 (68.9) | 21 (67.7) | ||
PS WHO 2 | 5 (11.1) | 4 (6.5) | 5 (11.1) | 0 | ||
Tumor length median (range) cm | 5 (1-11.5) | 6 (1-12) | 0.033 | 5 (1-11.5) | 6 (3-12) | 0.035 |
Upper thoracic tumor | 1 (2.2) | 10 (16.1) | <0.001 | 1 (2.2) | 1 (3.2) | 0.68 |
Middle thoracic tumor | 6 (13.3) | 24 (38.7) | 6 (13.3) | 7 (22.6) | ||
Lower thoracic tumor | 38 (84.4) | 28 (45.2) | 38 (84.4) | 23 (74.2) | ||
¶ SCC | 7 (15.9) | 32 (51.6) | <0.001 | 7 (15.9) | 10 (32.3) | 0.16 |
Adenocarcinoma | 37 (84.1) | 30 (48.4) | 37 (84.1) | 21 (67.7) | ||
Disease stage IIA | 19 (42.2) | 14 (22.6) | 0.028 | 19 (42.2) | 8 (25.8) | 0.24 |
Disease stage IIB | 6 (13.3) | 8 (12.9) | 6 (13.3) | 6 (19.4) | ||
Disease stage III | 20 (44.4) | 40 (64.5) | 20 (44.4) | 17 (54.8) | ||
Clinical ‡ T1 | 0 (0) | 2 (3.2) | 0.072 | 0 (0) | 1 (3.2) | 0.84 |
Clinical T2 | 15 (33.3) | 13 (21.0) | 15 (33.3) | 10 (32.3) | ||
Clinical T3 | 26 (57.8) | 31 (50.0) | 26 (57.8) | 17 (54.8) | ||
Clinical T4 | 4 (8.9) | 16 (25.8) | 4 (8.9) | 3 (9.7) | ||
Clinical § N1 | 24 (53.3) | 42 (73.7) | 0.039 | 24 (53.3) | 22 (71) | 0.031 |